Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion
MT Newswires Live
2 hours ago
Novartis (NVS) has signed an option and licensing agreement with South Korean biotech Alteogen to develop and sell subcutaneous versions of multiple Novartis drugs using its ALT-B4 technology, Alteogen said Wednesday.
The company said ALT-B4 is designed to convert biologic medicines typically given through intravenous infusions into faster injections under the skin.
If Novartis exercises all options and all milestones are met, Alteogen could receive up to $3.223 billion, including option fees, development and commercial milestones, and royalties on product sales, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.